拉贝洛尔联合拜新同治疗妊娠期高血压疾病的疗效观察  

Efficacy observation of labetalol combined with Adalat in the treatment of hypertension disorder complicating pregnancy

作　　者：范冬林[1] FAN Dong-lin(Beijing Fangshan District Maternal and Child Health Hospital,Beijing 102488,China)

机构地区：[1]北京市房山区妇幼保健院,102488

出　　处：《中国现代药物应用》2023年第7期97-99,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探究拉贝洛尔联合硝苯地平控释片(商品名:拜新同)治疗妊娠期高血压疾病(HDCP)的临床效果。方法84例HDCP患者,以随机数字表法分为常规组与研究组,各42例。常规组予以拜新同治疗,研究组在常规组基础上联合拉贝洛尔治疗。比较两组临床疗效、不良反应发生率及治疗前后病情相关指标[收缩压(SBP)、舒张压(DBP)、胎儿脐动脉SBP和DBP比值(S/D比值)、24 h尿蛋白定量]水平。结果研究组总有效率95.24%高于常规组的80.95%,差异有统计学意义(P<0.05)。治疗后,两组SBP、DBP、S/D比值、24 h尿蛋白定量均低于本组治疗前,且研究组SBP(125.61±9.24)mm Hg(1 mm Hg=0.133 kPa)、DBP(75.83±5.63)mm Hg、S/D比值(2.06±0.47)、24 h尿蛋白定量(0.17±0.04)g/24 h均低于常规组的(137.32±10.61)mm Hg、(84.64±6.79)mm Hg、(2.45±0.51)、(0.23±0.07)g/24 h,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论拉贝洛尔联合拜新同治疗HDCP具有显著效果,能有效控制患者血压,减轻症状,且安全性较高。Objective To investigate the clinical effect of labetalol combined with nifedipine controlled release tablets(trade name:Adalat)in the treatment of hypertension disorder complicating pregnancy(HDCP).Methods A total of 84 patients with HDCP were divided into the conventional group and the research group according to the random numerical table,with 42 cases in each group.The conventional group was treated with Adalat,and the research group was treated with labetalol on the basis of the conventional group.Both groups were compared in terms of clinical efficacy,incidence of adverse reactions,and the levels of condition-related indexes[systolic blood pressure(SBP),diastolic blood pressure(DBP),systolic/diastolic(S/D)ratio of umbilical artery,and 24-h urinary protein quantification].Results The total effective rate of 95.24%in the research group was higher than that of 80.95%in the conventional group,and the difference was statistically significant(P<0.05).After treatment,SBP,DBP,S/D ratio and 24-h urinary protein quantification in both groups were lower than those before treatment in this group;the research group had SBP of(125.61±9.24)mm Hg(1 mm Hg=0.133 kPa),DBP of(75.83±5.63)mm Hg,S/D ratio of(2.06±0.47),and 24-h urinary protein quantification of(0.17±0.04)g/24 h,which were lower than those of(137.32±10.61)mm Hg,(84.64±6.79)mm Hg,(2.45±0.51),and(0.23±0.07)g/24 h in the conventional group;the differences were statistically significant(P<0.05).The differences were not statistically significant when comparing the incidence of adverse reactions between the two groups(P>0.05).Conclusion Labetalol combined with Adalat has a significant effect in the treatment of HDCP,which can effectively control patients'blood pressure and reduce symptoms with high safety.

关 键 词：拉贝洛尔 硝苯地平控释片 妊娠期高血压疾病 

分 类 号：R714.246[医药卫生—妇产科学]